Psychedelic Psychiatry's Brave New World.
Cell
; 181(1): 24-28, 2020 04 02.
Article
em En
| MEDLINE
| ID: mdl-32243793
ABSTRACT
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psilocibina
/
Agonistas do Receptor 5-HT2 de Serotonina
/
Alucinógenos
/
Transtornos Mentais
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article